A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Inclusion Criteria:

• Participants who previously participated in EP0132 (NCT05109234) and/or N01269 (NCT04666610) and qualify for entry into EP0224 as per the EP0132 or N01269 protocolwith a confirmed diagnosis of childhood absence epilepsy (CAE) or juvenile absenceepilepsy (JAE)

• Participants for whom a reasonable benefit from long-term administration ofBrivaracetam (BRV) is expected in the opinion of the Investigator

• Male and female A male participant must agree to use contraception during thetreatment period and for at least 2 days after the final dose of investigationalmedicinal product (IMP) and refrain from donating sperm during this period.

A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

◦ Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 2 days after the final dose of IMP.

• Capable of and provides informed consent/assent, and the participant's parent/legalrepresentative/caregiver provides signed informed consent for minor participants,which includes compliance with the requirements and restrictions listed in theInformed Consent form (ICF)/Assent form and in this protocol

Exclusion Criteria:

• Participant has a history or presence of paroxysmal nonepileptic seizures

• Participant has severe medical, neurological, or psychiatric disorders or laboratoryvalues which could, at the discretion of the Investigator, affect safe participationin the study or would preclude appropriate study participation

• Participant has hepatic impairment (Child Pugh Score A, B, or C) based on theInvestigator's assessment

• Participant has active suicidal ideation prior to study entry as indicated by apositive response ("Yes") to either Question 4 or Question 5 of the Columbia-SuicideSeverity Rating Scale (C-SSRS) (for participants 6 years of age or older) orclinical judgment (for participants younger than 6 years of age). The participantshould be referred immediately to a Mental Healthcare Professional

• Participant has any medical or psychiatric condition that, in the opinion of theInvestigator, could jeopardize or would compromise the participant's ability toparticipate in this study

• Participant has known fructose intolerance or a known hypersensitivity to anycomponents of BRV or excipients or a drug with similar chemical structure

• Concomitant use of carbamazepine, felbamate, gabapentin, oxcarbazepine,phenobarbital, phenytoin, tiagabine, or vigabatrin

• Participant is receiving any investigational drugs or using any experimental devicesin addition to BRV

• Participant meets a mandatory withdrawal criterion for N01269 or EP0132 or isexperiencing an ongoing Serious adverse event (SAE)

• Participant has poor compliance with the visit schedule or IMP intake in thepreceding study in the opinion of the Investigator